| Date | Title | Description | Source |
| 19.01.2023 | EQRx promised to deliver cutting-edge drugs at half the cost... | EQRx cofounder and executive chairman Alexis Borisy EQRx This story is available exclusively to Insi... | businessin... |
| 12.01.2023 | Alphabet's Verily announces layoffs amid strategic restructu... | Photo: filadendron/Getty Images
Alphabet's life science subsidiary Verily's new CEO, Stephen Gillet... | mobihealth... |
| 12.09.2022 | Alphabet's Verily raises $1B to expand precision health busi... | Photo: JL Images/Getty Images
Alphabet's life science offshoot Verily announced it had raised $1 bi... | mobihealth... |
| 02.08.2022 | Investing in IDRx | HIV ravaged entire communities before antiretroviral cocktail therapies helped turn the tide. Cockta... | a16z.com/2... |
| 18.01.2022 | EQRx Announces Two Lancet Oncology Publications of Positive ... | Results from the pivotal Phase 3 GEMSTONE-301 study demonstrated that sugemalimab, an anti-PD-L1 ant... | marketscre... |
| 16.11.2021 | EQRx Launches “Remaking Medicine: On The Record” Investor Vi... | EQRx, a new type of pharmaceutical company committed to developing and delivering important new medi... | marketscre... |
| 26.10.2021 | Why serial biotech entrepreneur Alexis Borisy wants to stop ... | The EQRx cofounder and chairman Alexis Borisy. EQRx This story is available exclusively to Insider s... | businessin... |
| 23.08.2021 | A new kind of biotech is aiming to undercut Big Pharma with ... | A scientist works in a lab at the pharmaceutical company Pfizer. Pat Greenhouse/The Boston Globe via... | businessin... |
| 10.08.2021 | UPDATED: Virtually unknown mRNA upstart rides SPAC t... | Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmar... | endpts.com... |
| 09.08.2021 | AbbVie hands back headline drug in $63B Allergan buyout to M... | In one of the more unlikely bidding wars in recent biopharma memory, a British tobacco giant and a U... | endpts.com... |
| 06.08.2021 | Court decision pushes FDA to make historical shift and... | EQRx, a would-be drug pricing disruptor that has emerged as an investor darling, has everything but ... | endpts.com... |
| 06.08.2021 | Court decision pushes FDA to make historical shift and... | Rack up another delay for Novavax $NVAX on the crucial EUA front.
The biotech’s Q2 review dropped a... | endpts.com... |
| 06.08.2021 | Court decision pushes FDA to make historical shift and... | Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO T... | endpts.com... |
| 06.08.2021 | FDA orders clinical hold on Aprea's p53 reactivator a... | Little Aprea Therapeutics just tripped yet again on its rocky path to develop a drug that can ... | endpts.com... |
| 06.08.2021 | Chinese startup with Merck vet at the helm acquires righ... | With the Chinese drug market starting to bear fruit, Western drugmakers have looked to wiggle... | endpts.com... |
| 06.08.2021 | Senate Dems call to add Medicare drug price negotiation... | Don’t forget to include drug pricing reforms in the upcoming $3.5 trillion reconciliatio... | endpts.com... |
| 06.08.2021 | Bitcoin mining is having a moment right now, but will it las... | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 06.08.2021 | Sanofi wins approval for Lumizyme successor, although u... | It’s not yet clear how many patients will actually take it, but for the first time in 15 years, ... | endpts.com... |
| 06.08.2021 | Court decision pushes FDA to make historical shift and regul... | Moderna’s little business deal with Autolus earlier this week looks like a predinner snack ahead of ... | endpts.com... |
| 06.08.2021 | Vertex taps longtime commercial lead to fill two-year CO... | For the first time in two years, Vertex has a COO.
Stuart Arbuckle
The cystic fibrosis drug... | endpts.com... |
| 06.08.2021 | Court decision pushes FDA to make historical shift and... | Normally, new generic drug competition can enter the market for one or some of the approved indicati... | endpts.com... |
| 06.08.2021 | Court decision pushes FDA to make historical shift and regul... | Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in yo... | endpts.com... |
| 28.05.2021 | CStone Announces the First-in-Class Registrational Clinical ... | Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to successfully improve pr... | en.prnasia... |
| 12.01.2021 | Affordable drug developer EQRx lands $500M | EQRx has raised $500 million in a Series B, bringing the company's total fundraising to about $750 m... | pitchbook.... |
| 12.01.2021 | One year after founding, startup EQRx raises $500M to advanc... | Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during ... | medcitynew... |
| 12.01.2021 | Daily funding roundup - January 11th, 2021 | Aulos Bioscience has raised $40M; Komodo Health landed $44M; EQRx secured $500M
Hello Ralphie: Hell... | vator.tv/n... |
| 11.01.2021 | EQRx : Scales Disruptive Model of Important New Medicines at... | EQRx, a company committed to developing and delivering important new medicines at lower prices, toda... | marketscre... |
| 11.01.2021 | EQRx Closes $500 Million Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--EQRx, a company committed to developing and delivering important ... | citybizlis... |
| 11.01.2021 | EQRx scores $500M to drive its disruptive drug pricing m... | Nearly a year into its mission of rewriting the rules of drug pricing, EQRx has made a few key ... | endpts.com... |
| 18.01.2020 | Pharma startup EQRx launches with a $200 million Series A to... | Happy weekend, folks. It’s been really cold here with freezing rain. Anyway, it’s not clear why we m... | techstartu... |
| 17.01.2020 | EQRx Raises $200 Million To Make Medicines More Affordable | EQRx recently announced it is launching to create novel patent-protected medicines for affordable pr... | pulse2.com... |
| 14.01.2020 | EQRx Launches with $200M Series A Financing |
CAMBRIDGE, MA, EQRx is launching with $200M in Series A financing led by GV, ARCH Venture Partners... | vcnewsdail... |
| 13.01.2020 | EQRx Launches With $200M Series A For Cheaper Drugs | 29 Shares Email Facebook Twitter LinkedIn
We’ve all read the headlines of people with diseases or i... | news.crunc... |
| 13.01.2020 | EQRx Launches With $200M Series A For Cheaper Drugs | 27 Shares Email Facebook Twitter LinkedIn
We’ve all read the headlines of people with diseases or i... | news.crunc... |
| 12.01.2020 | With $200M Series A, EQRx aims to tackle high drug prices | The company aims to provide what it calls a market-based solution for the rising cost of drugs by ch... | medcitynew... |
| 12.01.2020 | JPM: JetBlue, but for biopharma: Borisy's EQRx nabs $200M, t... | SAN FRANCISCO—It's not news: Over time, biopharma companies have raised the price of new medicines e... | fiercebiot... |
| - | Investors aren't buying EQRx's pitch for 'radically lower' d... | EQRx CEO Melanie Nallicheri. EQRx This story is available exclusively to Insider subscribers. Become... | businessin... |
| - | One year after founding, startup EQRx raises $500M to advanc... | A high-powered startup has raised $500 million toward its goal of making drugs for cancer and other ... | medcitynew... |
| - | With $200M Series A, EQRx aims to tackle high drug prices | In a story summarizing biopharma executives’ forecasts for 2020 last weekend, one said that while it... | medcitynew... |
